MARKET

YMTX

YMTX

Yumanity Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.050
-0.110
-9.48%
Closed 16:35 05/24 EDT
OPEN
1.160
PREV CLOSE
1.160
HIGH
1.190
LOW
1.040
VOLUME
59.59K
TURNOVER
--
52 WEEK HIGH
16.89
52 WEEK LOW
0.9500
MARKET CAP
11.39M
P/E (TTM)
-0.2732
1D
5D
1M
3M
1Y
5Y
Yumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02M
Yumanity Therapeutics press release (NASDAQ:YMTX): Q1 GAAP EPS of -$1.24. Collaboration revenue of $1.02M.
Seekingalpha · 05/12 20:52
BRIEF-Yumanity Therapeutics Reports Q1 2022 Results
reuters.com · 05/12 20:47
-- Earnings Flash (YMTX) YUMANITY THERAPEUTICS Reports Q1 Revenue $1M
MT Newswires · 05/12 16:48
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 04/01 13:11
Clever Leaves, Tilray top healthcare gainers; MEI Pharma, Icosavax lead losers' pack
Gainers: Clever Leaves CLVR +28%. Tilray Brands TLRY +13%. Cutera CUTR +11%. STRATA Skin Sciences SSKN +10%. Clarus Therapeutics (CRXT) +8%. Losers: MEI Pharma MEIP -58%. Icosavax ICVX -50%. Rezolute (RZLT) -9%. Alpha Tau Medical (DRTS) -8%. Yumanity Thera...
Seekingalpha · 03/25 14:02
Looking Into Yumanity Therapeutics's Return On Capital Employed
Benzinga Pro data, Yumanity Therapeutics (NASDAQ:YMTX) reported Q4 sales of $762.00 thousand. Earnings fell to a loss of $10.41 million, resulting in a 4.57% decrease from last quarter.
Benzinga · 03/25 13:54
BRIEF-Yumanity Therapeutics Reports Full-Year 2021 Financial Results
reuters.com · 03/24 21:19
Yumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04M
Yumanity Therapeutics press release (NASDAQ:YMTX): FY GAAP EPS of -$3.84. Collaboration Revenue of $8.04M (+16.5% Y/Y). As of December 31, 2021, cash, cash equivalents and investments were $36.5 million.
Seekingalpha · 03/24 20:51
More
No Data
Learn about the latest financial forecast of YMTX. Analyze the recent business situations of Yumanity Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average YMTX stock price target is 27.67 with a high estimate of 39.00 and a low estimate of 9.00.
High39.00
Average27.67
Low9.00
Current 1.050
EPS
Actual
Estimate
-0.90-0.68-0.45-0.23
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 70
Institutional Holdings: 22.78M
% Owned: 210.09%
Shares Outstanding: 10.84M
TypeInstitutionsShares
Increased
4
102.13K
New
3
31.60K
Decreased
6
82.06K
Sold Out
10
306.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman
N. Anthony Coles
President/Chief Executive Officer/Director
Richard Peters
Chief Financial Officer/Senior Vice President/Treasurer
Michael Wyzga
Senior Vice President/General Counsel/Secretary
Devin Smith
Lead Director/Independent Director
Richard Heyman
Independent Director
Patricia Allen
Independent Director
David Arkowitz
Independent Director
Kimberlee Drapkin
Independent Director
Jeffery Kelly
Independent Director
Cecil Pickett
Independent Director
Lynne Zydowsky
No Data
No Data
About YMTX
Yumanity Therapeutics Inc., formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's technology platform enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks. The Company's product candidate, YTX-7739, is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease and YTX-9184, in IND-enabling studies for the treatment of dementia with Lewy bodies. The Company's pipeline consists of additional programs for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) and frontotemporal lobar degeneration (FTLD) is undergoing research through Merck.

Webull offers kinds of Yumanity Therapeutics Inc stock information, including NASDAQ:YMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YMTX stock methods without spending real money on the virtual paper trading platform.